SMP201100003B - Agonisti del recettore GPR119 arilico e relativi utilizzi - Google Patents

Agonisti del recettore GPR119 arilico e relativi utilizzi

Info

Publication number
SMP201100003B
SMP201100003B SM201100003T SM201100003T SMP201100003B SM P201100003 B SMP201100003 B SM P201100003B SM 201100003 T SM201100003 T SM 201100003T SM 201100003 T SM201100003 T SM 201100003T SM P201100003 B SMP201100003 B SM P201100003B
Authority
SM
San Marino
Prior art keywords
receptor agonists
gpr119 receptor
aryl
aryl gpr119
agonists
Prior art date
Application number
SM201100003T
Other languages
English (en)
Other versions
SMAP201100003A (it
Inventor
Zuchun Zhao
Xin Chen
Jiangao Song
Jingyuan Ma
Christopher J Rabbat
Imad Nashashibi
Original Assignee
Metabolex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolex Inc filed Critical Metabolex Inc
Publication of SMAP201100003A publication Critical patent/SMAP201100003A/it
Publication of SMP201100003B publication Critical patent/SMP201100003B/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
SM201100003T 2008-06-20 2011-01-11 Agonisti del recettore GPR119 arilico e relativi utilizzi SMP201100003B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7455208P 2008-06-20 2008-06-20
PCT/US2009/047551 WO2010008739A2 (en) 2008-06-20 2009-06-16 Aryl gpr119 agonists and uses thereof

Publications (2)

Publication Number Publication Date
SMAP201100003A SMAP201100003A (it) 2011-03-07
SMP201100003B true SMP201100003B (it) 2011-11-11

Family

ID=41550941

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201100003T SMP201100003B (it) 2008-06-20 2011-01-11 Agonisti del recettore GPR119 arilico e relativi utilizzi

Country Status (15)

Country Link
US (1) US20110294836A1 (it)
EP (1) EP2303859A4 (it)
JP (1) JP2011524917A (it)
KR (1) KR20110026481A (it)
CN (1) CN102203074A (it)
AU (1) AU2009271414A1 (it)
BR (1) BRPI0914891A2 (it)
CA (1) CA2727174A1 (it)
CL (1) CL2010001496A1 (it)
IL (1) IL209785A0 (it)
MX (1) MX2010013876A (it)
RU (1) RU2010151352A (it)
SM (1) SMP201100003B (it)
WO (1) WO2010008739A2 (it)
ZA (1) ZA201009009B (it)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
CN101754962B (zh) 2007-07-19 2013-12-25 赛马拜制药公司 作为rup3或gpr119受体的激动剂治疗糖尿病和代谢性病症的n-氮杂环状经取代吡咯、吡唑、咪唑、三唑和四唑衍生物
JP5711655B2 (ja) * 2008-03-31 2015-05-07 シマベイ セラピューティクス， インコーポレーテッド オキシメチレンアリール化合物およびその使用
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
WO2009143389A1 (en) 2008-05-21 2009-11-26 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
US20110294836A1 (en) * 2008-06-20 2011-12-01 Metabolex, Inc. Aryl gpr119 agonists and uses thereof
JPWO2010013849A1 (ja) 2008-08-01 2012-01-12 日本ケミファ株式会社 Ｇｐｒ１１９作動薬
TWI396689B (zh) 2008-11-14 2013-05-21 Amgen Inc 作為磷酸二酯酶１０抑制劑之吡衍生物
HRP20120920T1 (hr) 2008-11-14 2013-01-31 Theravance, Inc. Spojevi 4-[2-(2 fluorofenoksimetil)fenil]piperidina
TW201030001A (en) 2008-11-14 2010-08-16 Amgen Inc Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors
CA2746307C (en) 2008-12-17 2013-11-19 Amgen Inc. Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors
AU2010264720A1 (en) 2009-06-24 2011-12-08 Boehringer Ingelheim International Gmbh New compounds, pharmaceutical composition and methods relating thereto
WO2010149685A1 (en) 2009-06-24 2010-12-29 Boehringer Ingelheim International Gmbh New compounds, pharmaceutical composition and methods relating thereto
CN102482278B (zh) 2009-06-29 2015-04-22 因塞特公司 作为pi3k抑制剂的嘧啶酮类
JPWO2011025006A1 (ja) 2009-08-31 2013-01-31 日本ケミファ株式会社 Ｇｐｒ１１９作動薬
WO2011030139A1 (en) 2009-09-11 2011-03-17 Astrazeneca Ab 4- (pyrimidin-2-yl) -piperazine and 4- (pyrimidin-2-yl) -piperidine derivatives as gpr119 modulators
ES2497566T3 (es) 2009-10-01 2014-09-23 Cymabay Therapeutics, Inc. Sales de tetrazol-1-il-fenoximetil-tiazol-2-il-piperidinil-pirimidina sustituida
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
JP2013047188A (ja) * 2009-12-24 2013-03-07 Nippon Chemiphar Co Ltd Ｇｐｒ１１９作動薬
EP2523945A1 (en) 2010-01-11 2012-11-21 Theravance, Inc. 1 - (2 - phenoxymethylphenyl) piperazine compounds as serotonin and norepinephrine reuptake inhibitors
CN102971304A (zh) 2010-02-01 2013-03-13 日本化学医药株式会社 Gpr119激动剂
US20130109703A1 (en) 2010-03-18 2013-05-02 Boehringer Ingelheim International Gmbh Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions
ES2543064T3 (es) * 2010-03-22 2015-08-14 Theravance Biopharma R&D Ip, Llc Compuestos de 1-(2-fenoximetilheteroaril)piperidina y piperazina
EP2558463A1 (en) 2010-04-14 2013-02-20 Incyte Corporation Fused derivatives as i3 inhibitors
CN103221404B (zh) 2010-05-13 2015-12-16 安姆根有限公司 可用作pde10抑制剂的不饱和氮杂环化合物
ES2660611T3 (es) 2010-05-27 2018-03-23 Bayer Cropscience Ag Derivados de ácido piridinilcarboxílico como fungicidas
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
ES2676209T3 (es) 2010-06-23 2018-07-17 Metabolex Inc. Composiciones de 5-etil-2-{4-[4-(4-tetrazol-1-il-fenoximetil)-tiazol-2-il]-piperidin-1-il}-pirimidina
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
WO2012025811A1 (en) 2010-08-23 2012-03-01 Lupin Limited Indolylpyrimidines as modulators of gpr119
SG188361A1 (en) 2010-09-01 2013-04-30 Arena Pharm Inc Non-hygroscopic salts of 5-ht2c agonists
SG10201506870PA (en) 2010-09-01 2015-10-29 Arena Pharm Inc Salts of lorcaserin with optically active acids
WO2012030951A1 (en) 2010-09-01 2012-03-08 Arena Pharmaceuticals, Inc. Fast-dissolve dosage forms of 5-ht2c agonists
KR101913442B1 (ko) 2010-09-01 2018-10-30 에자이 알앤드디 매니지먼트 가부시키가이샤 체중 관리에 유용한 5-ｈｔ2ｃ 작동제의 변형-방출 투여 형태
AU2011305525B2 (en) * 2010-09-22 2016-08-18 Arena Pharmaceuticals, Inc. Modulators of the GPR119 receptor and the treatment of disorders related thereto
JP2014001144A (ja) * 2010-10-08 2014-01-09 Nippon Chemiphar Co Ltd Ｇｐｒ１１９作動薬
AU2011333472A1 (en) 2010-11-26 2013-06-06 Lupin Limited Bicyclic GPR119 modulators
TW201249844A (en) 2010-12-20 2012-12-16 Incyte Corp N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
US20120184572A1 (en) * 2011-01-13 2012-07-19 Metabolex, Inc. Aryl gpr119 agonists and uses thereof
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
EP2686312B1 (en) * 2011-03-14 2016-08-31 Boehringer Ingelheim International GmbH N-cyclopropyl-n-piperidinylbenzamides as gpr119 modulators
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
CN103501612B (zh) 2011-05-04 2017-03-29 阿里亚德医药股份有限公司 抑制表皮生长因子受体导致的癌症中细胞增殖的化合物
ES2602813T3 (es) 2011-06-09 2017-02-22 Rhizen Pharmaceuticals S.A. Nuevos compuestos como moduladores de GPR-119
TWI648277B (zh) 2011-09-02 2019-01-21 美商英塞特控股公司 作為ｐｉ３ｋ抑制劑之雜環基胺
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8809372B2 (en) 2011-09-30 2014-08-19 Asana Biosciences, Llc Pyridine derivatives
US9199975B2 (en) 2011-09-30 2015-12-01 Asana Biosciences, Llc Biaryl imidazole derivatives for regulating CYP17
US9926309B2 (en) 2011-10-05 2018-03-27 The Board Of Trustees Of The Leland Stanford Junior University Pi-kinase inhibitors with anti-infective activity
EP2763532B1 (en) 2011-10-05 2018-09-19 The Board of Trustees of the Leland Stanford Junior University Pi-kinase inhibitors with broad spectrum anti-infective activity
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
JP6469567B2 (ja) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
US9013997B2 (en) 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
EP2872127A1 (en) 2012-07-11 2015-05-20 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
US8729263B2 (en) 2012-08-13 2014-05-20 Novartis Ag 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
MX379228B (es) 2013-03-15 2025-03-10 Global Blood Therapeutics Inc Compuestos y usos de estos para la modulación de la hemoglobina.
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
DE102013008118A1 (de) 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
CN105636953B (zh) 2013-07-31 2018-01-02 诺华股份有限公司 1,4‑二取代的哒嗪衍生物及其用于治疗与smn缺乏相关的病症的用途
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
EP3094629B1 (en) 2014-01-17 2018-08-22 Novartis AG 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
EP3094627B1 (en) 2014-01-17 2018-08-22 Novartis AG 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2
WO2015112847A1 (en) * 2014-01-24 2015-07-30 Confluence Life Sciences, Inc. Arylpyridinone itk inhibitors for treating inflammation and cancer
CA2939382A1 (en) 2014-02-14 2015-08-20 Takeda Pharmaceutical Company Limited Pyrazines modulators of gpr6
WO2015138273A1 (en) * 2014-03-13 2015-09-17 Merck Sharp & Dohme Corp. 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
JP6769963B2 (ja) 2014-08-29 2020-10-14 ティエエッセ ファルマ ソチエタ レスポンサビリタ リミタータ α−アミノ−β−カルボキシムコン酸セミアルデヒド脱炭酸酵素の阻害剤
KR20170103838A (ko) 2015-01-23 2017-09-13 컨플루언스 라이프 사이언시스, 인코포레이티드 염증 및 암의 치료를 위한 헤테로시클릭 itk 저해제
CA3285092A1 (en) 2015-02-27 2025-11-29 Incyte Holdings Corporation Salts of pi3k inhibitor and processes for their preparation
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
WO2016203404A1 (en) 2015-06-19 2016-12-22 Novartis Ag Compounds and compositions for inhibiting the activity of shp2
EP3310774B1 (en) 2015-06-19 2020-04-29 Novartis AG Compounds and compositions for inhibiting the activity of shp2
US10308660B2 (en) 2015-06-19 2019-06-04 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
US10421756B2 (en) 2015-07-06 2019-09-24 Rodin Therapeutics, Inc. Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase
RS62639B1 (sr) 2015-07-06 2021-12-31 Alkermes Inc Hetero-halo inhibitori histonskih deacetilaza
US11091472B2 (en) 2016-02-26 2021-08-17 The Regents Of The University Of California PI-kinase inhibitors with anti-infective activity
HUE057838T2 (hu) 2016-06-07 2022-06-28 Jacobio Pharmaceuticals Co Ltd SHP2 inhibitorokként hasznos új heterociklusos származékok
RU2744988C2 (ru) 2016-06-14 2021-03-17 Новартис Аг Соединения и композиции для подавления активности shp2
PT3971177T (pt) 2016-07-20 2024-07-30 Novartis Ag Derivados de aminopiridina e a sua utilização como inibidores seletivos de alk-2
CN109862896A (zh) 2016-08-03 2019-06-07 西玛贝医药公司 用于治疗炎症性胃肠疾病或胃肠病症的氧亚甲基芳基化合物
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
US11260049B2 (en) 2016-09-20 2022-03-01 Glaxosmithkline Intellectual Property (No. 2) Limited TRPV4 antagonists
TW201825458A (zh) 2016-09-20 2018-07-16 英商葛蘭素史克智慧財產（第二）有限公司 Ｔｒｐｖ４拮抗劑
WO2018055527A1 (en) 2016-09-20 2018-03-29 Glaxosmithkline Intellectual Property (No.2) Limited Trpv4 antagonists
ES2964956T3 (es) 2017-01-10 2024-04-10 Novartis Ag Combinación farmacéutica que comprende un inhibidor de ALK y un inhibidor de SHP2
MD3570834T2 (ro) 2017-01-11 2022-04-30 Alkermes Inc Inhibitori biciclici ai histon deacetilazei
US10316038B2 (en) 2017-01-25 2019-06-11 Aclaris Therapeutics, Inc. Pyrrolopyrimidine ITK inhibitors for treating inflammation and cancer
TWI664175B (zh) 2017-03-23 2019-07-01 大陸商北京加科思新藥研發有限公司 用於作為shp2抑制劑之新穎雜環衍生物
JP7152471B2 (ja) 2017-08-07 2022-10-12 ロダン・セラピューティクス，インコーポレーテッド ヒストン脱アセチル化酵素の二環阻害剤
AU2019220746A1 (en) 2018-02-15 2020-08-27 Nuvation Bio Inc. Heterocyclic compounds as kinase inhibitors
KR102526964B1 (ko) 2018-02-26 2023-04-28 길리애드 사이언시즈, 인코포레이티드 Hbv 복제 억제제로서의 치환된 피롤리진 화합물
CN120053645A (zh) 2018-06-01 2025-05-30 因赛特公司 治疗pi3k相关病症的给药方案
CN112839935A (zh) 2018-09-26 2021-05-25 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物
CA3121202A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
JP7701051B2 (ja) 2019-03-21 2025-07-01 ザ ボード オブ トラスティス オブ ザ リーランド スタンフォード ジュニア ユニヴァーシティー Ｐｉ４－キナーゼ阻害剤及びその使用方法
WO2021102258A1 (en) 2019-11-22 2021-05-27 Incyte Corporation Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor
JP7745559B2 (ja) 2020-02-28 2025-09-29 キャリーオペ，インク． Ｇｐｒ４０アゴニスト
BR112022023359A2 (pt) 2020-05-19 2023-04-18 Kallyope Inc Ativadores de ampk
CN115968289B (zh) 2020-06-16 2025-09-30 因赛特公司 用于治疗贫血的alk2抑制剂
JP2023531726A (ja) 2020-06-26 2023-07-25 キャリーオペ，インク． Ａｍｐｋアクチベーター

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3108117A (en) * 1959-02-12 1963-10-22 Mead Johnson & Co 3-benzyl-1, 2-diloweralkyl-3-pyrrolidinols
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
DE2701705A1 (de) * 1976-01-28 1977-08-04 Sandoz Ag Neue organische verbindungen, ihre verwendung und herstellung
AU4444393A (en) * 1992-09-01 1994-03-10 Zeneca Limited Pyrrolidine derivatives
GB9310713D0 (en) * 1993-05-24 1993-07-07 Zeneca Ltd Aryl substituted heterocycles
EP0755923B1 (en) * 1995-01-23 2005-05-04 Daiichi Suntory Pharma Co., Ltd. Ameliorant or remedy for symptoms caused by Ischemic diseases and Phenylpiperidine compounds useful therefor
KR100384979B1 (ko) * 1995-09-07 2003-10-17 에프. 호프만-라 로슈 아게 심부전증및신부전증치료용의신규한4-(옥시알콕시페닐)-3-옥시-피페리딘
US5792769A (en) * 1995-09-29 1998-08-11 3-Dimensional Pharmaceuticals, Inc. Guanidino protease inhibitors
DE69731070T2 (de) * 1996-07-22 2005-03-17 Daiichi Suntory Pharma Co., Ltd. Arylpiperidinol und arylpiperidin-derivate und sie enthaltende arzneimittel
US6274735B1 (en) * 1998-08-10 2001-08-14 Hoffmann-La Roche Inc. Process and intermediates for preparation of substituted piperidines
IT1303737B1 (it) * 1998-11-11 2001-02-23 Smithkline Beecham Spa Derivati fenilpiperidinici procedimento per la loro preparazione eloro uso come ligandi del recettore orl-1.
GB9912416D0 (en) * 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
JP2004534017A (ja) * 2001-04-27 2004-11-11 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｂａｃｅのインヒビター
WO2003091216A1 (en) * 2002-04-25 2003-11-06 Sumitomo Pharmaceuticals Co., Ltd. Novel piperidine derivative
GB0308333D0 (en) * 2003-04-10 2003-05-14 Glaxo Group Ltd Novel compounds
JP2007505951A (ja) * 2003-06-13 2007-03-15 シエーリング アクチエンゲゼルシャフト Ｃｃｒ−５アンタゴニストとしてのキノリルアミド誘導体類
KR20060036105A (ko) * 2003-07-29 2006-04-27 제논 파마슈티칼스 인크. 피리딜 유도체 및 그의 치료제로서의 용도
US7235641B2 (en) * 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
TW200538433A (en) * 2004-02-24 2005-12-01 Irm Llc Immunosuppressant compounds and compositiions
JP4787529B2 (ja) * 2004-04-09 2011-10-05 大塚製薬株式会社 医薬組成物
DK1773772T3 (da) * 2004-06-08 2010-09-13 Nsab Af Neurosearch Sweden Ab Nye disubstituerede phenylpiperidiner/piperaziner som modulatorer af dopaminneurotransmission
GB0428526D0 (en) * 2004-12-30 2005-02-09 Novartis Ag Organic compounds
MY148521A (en) * 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
KR20070107040A (ko) * 2005-02-16 2007-11-06 쉐링 코포레이션 Ｃｘｃｒ3 길항제 활성을 갖는 헤테로아릴-치환된피라지닐-피페라진-피페리딘
GB0504850D0 (en) * 2005-03-09 2005-04-13 Novartis Ag Organic compounds
EP1707202A1 (de) * 2005-03-31 2006-10-04 Speedel Experimenta AG Organische Verbindungen
JP2008543828A (ja) * 2005-06-15 2008-12-04 ファイザー・リミテッド ドーパミン作動薬としての３−フェニルアゼチジン誘導体
JP2009508861A (ja) * 2005-09-16 2009-03-05 アリーナ ファーマシューティカルズ， インコーポレイテッド 代謝の調節因子および代謝に関連する障害の処置
WO2008025800A1 (en) * 2006-08-30 2008-03-06 Biovitrum Ab (Publ) Pyrimidine compounds for treating gpr119 related disorders
BRPI0719941A2 (pt) * 2006-12-06 2014-04-22 Smithkline Beecham Corp Composto, uso de um composto, método para o tratamento de distúrbios ou condições metabólicos, composição farmacêutica, e, processo para a preparação de uma composição farmacêutica
US7638541B2 (en) * 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
EP2014656A3 (en) * 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC New heteocyclic h3 antagonists
US20100249163A1 (en) * 2007-12-04 2010-09-30 Daniel Dube Renin inhibitors
US20110294836A1 (en) * 2008-06-20 2011-12-01 Metabolex, Inc. Aryl gpr119 agonists and uses thereof
JPWO2010013849A1 (ja) * 2008-08-01 2012-01-12 日本ケミファ株式会社 Ｇｐｒ１１９作動薬
WO2010048149A2 (en) * 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease

Also Published As

Publication number Publication date
WO2010008739A3 (en) 2010-04-22
CL2010001496A1 (es) 2011-08-05
KR20110026481A (ko) 2011-03-15
EP2303859A4 (en) 2012-08-22
SMAP201100003A (it) 2011-03-07
RU2010151352A (ru) 2012-07-27
JP2011524917A (ja) 2011-09-08
BRPI0914891A2 (pt) 2015-11-24
EP2303859A2 (en) 2011-04-06
CN102203074A (zh) 2011-09-28
IL209785A0 (en) 2011-02-28
WO2010008739A2 (en) 2010-01-21
AU2009271414A1 (en) 2010-01-21
US20110294836A1 (en) 2011-12-01
ZA201009009B (en) 2012-04-25
MX2010013876A (es) 2011-03-04
CA2727174A1 (en) 2010-01-21

Similar Documents

Publication Publication Date Title
SMP201100003B (it) Agonisti del recettore GPR119 arilico e relativi utilizzi
BRPI1015921A2 (pt) agonistas de gpr119
IL208919A0 (en) Gpr119 receptor agonists
DK2335370T3 (da) Organ-på-en-chip-anordning
DK2352469T3 (da) Indføringsindretning
NO2015017I1 (no) Apremilast
EP2364330A4 (en) MULTI BLOCK POLYMERS
EP3988147C0 (en) INSERT SET
EP2490709A4 (en) PEPTIDIC GLP-2 AGONISTS
BRPI0807911A2 (pt) Agonistas de alfa2c adrenorreceptor
ATE522696T1 (de) Sicherungseinrichtung
BRPI0918056A2 (pt) Diaminopirimidinas substituídas por 4-alquila
EP2337157A4 (en) CONNECTOR
ES1070883Y (es) Dispositivo elevador
ES1067341Y (es) Dispositivo perforador-fijador
BR112012002824A2 (pt) agonistas de receptor de esfingosina-1-fosfato
EP2358763A4 (en) POLYMER COMPOSITION
EP2442839A4 (en) MIXTURES OF BLOCK COPOLYMERS
BRPI0907898A2 (pt) Antagonistas do receptor da melanocortina-5-3- substituído-1,4-diazepan-2-ona
MA31558B1 (fr) Arriere-plan technologique
DE502009000266D1 (de) Kalander
NO20081795A (no) Støtteinnretning
FI20080679A0 (fi) Nasta
DE502008002565D1 (de) Bearbeitungsvorrichtung
UA18865S (uk) Ветеринарне свідоцтво